Dr. Chu Discusses CNS Penetration of Ceritinib

Quincy Chu, MD
Published: Wednesday, Nov 12, 2014

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.

Ceritinib, unlike crizotinib, has substantial CNS penetration, Chus says. It has been shown in animal models that even if the cancer spreads into the brain, ceritinib can have some duration of control. Crizotinib has not demonstrated good CNS penetration, Chu says.

At the 2014 ESMO Congress, researchers provided an update on crizotinib-naïve patients. Chu says the median progression-free survival was approximately 18 months in this population — which is longer than crizotinib.

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.

Ceritinib, unlike crizotinib, has substantial CNS penetration, Chus says. It has been shown in animal models that even if the cancer spreads into the brain, ceritinib can have some duration of control. Crizotinib has not demonstrated good CNS penetration, Chu says.

At the 2014 ESMO Congress, researchers provided an update on crizotinib-naïve patients. Chu says the median progression-free survival was approximately 18 months in this population — which is longer than crizotinib.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x